parsaclisib

phosphatidylinositol 3-kinase delta (PI3Kdelta) inhibitor

Also Known As:

(4R)-4-(3-((1S)-1-(4-amino-3-methyl-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one; 2-Pyrrolidinone, 4-(3-((1S)-1-(4-amino-3-methyl-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)-, (4R)-; INCB050465

Networked: 16 relevant articles (5 outcomes, 10 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds

Experts

1.	Li, Jia: 3 articles (05/2022 - 11/2020)
2.	Zhao, Wanying: 2 articles (05/2022 - 01/2021)
3.	Verstovsek, Srdan: 2 articles (01/2022 - 01/2022)
4.	DeMarini, Douglas J: 2 articles (01/2021 - 01/2019)
5.	Chen, Xuejun: 2 articles (11/2020 - 01/2019)
6.	Yeleswaram, Swamy: 2 articles (11/2020 - 01/2020)
7.	Coronado, Cinthya: 1 article (05/2022)
8.	Fukuhara, Noriko: 1 article (05/2022)
9.	Gilmartin, Aidan: 1 article (05/2022)
10.	Izutsu, Koji: 1 article (05/2022)

Related Diseases

1.	Neoplasms (Cancer) 05/01/2022 - "We undertook a phase Ib study (CITADEL-111) evaluating safety, pharmacokinetics, and efficacy of parsaclisib in Japanese patients with relapsed or refractory B-cell malignancies. " 09/01/2023 - "Parsaclisib, a potent and highly selective PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory (R/R) B-cell malignancies. " 08/01/2023 - "Parsaclisib is a potent and highly selective PI3Kδ inhibitor that has shown clinical benefit in patients with relapsed/refractory (R/R) B-cell malignancies. " 01/01/2019 - "Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies." 01/01/2020 - "SIGNIFICANCE STATEMENT: The preclinical properties described here provide the mechanism of action and support clinical investigations of parsaclisib as a therapy for B-cell malignancies. "
2.	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 09/01/2023 - "This phase 2 study (CITADEL-203; NCT03126019, EudraCT 2017-001624-22) assessed efficacy and safety of parsaclisib monotherapy in patients with R/R follicular lymphoma (FL). " 09/01/2023 - "Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study." 07/26/2023 - "Parsaclisib is a potent and highly selective PI3Kδ inhibitor that has shown clinical benefit with monotherapy in a phase 2 study in relapsed or refractory (R/R) follicular lymphoma (FL). " 07/26/2023 - "Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study."
3.	Sialadenitis 09/01/2021 - "Parsaclisib mediated improvement of salivary gland inflammation coincided with reduced B-cell activating cytokine (BAFF) in saliva. " 09/01/2021 - "Oral parsaclisib treatment ameliorated the severity of salivary gland inflammation and reduced circulating levels of autoantibodies. " 09/01/2021 - "Parsaclisib reduced autoreactive B-cells and autoantibody levels, and significantly improved nephritis and salivary gland inflammation. "
4.	Nephritis 09/01/2021 - "Parsaclisib effectively preserved renal function as measured by glomerular filtration rate, abrogated histopathological evidence of nephritis, modulated discrete immune cell subsets, and decreased anti-dsDNA antibody level. " 09/01/2021 - "Parsaclisib reduced autoreactive B-cells and autoantibody levels, and significantly improved nephritis and salivary gland inflammation. "
5.	Systemic Lupus Erythematosus (Libman-Sacks Disease) 09/01/2021 - "We characterized the potential of parsaclisib to ameliorate autoimmune mechanisms implicated in the pathophysiology of systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). " 09/01/2021 - "The PI3Kδ inhibitor parsaclisib ameliorates pathology and reduces autoantibody formation in preclinical models of systemic lupus erythematosus and Sjӧgren's syndrome."

Related Drugs and Biologics

1.	itacitinib
2.	epacadostat
3.	Bendamustine Hydrochloride
4.	obinutuzumab
5.	Autoantibodies
6.	parsaclisib
7.	navitoclax
8.	imetelstat
9.	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)
10.	Telomerase (Telomerase Reverse Transcriptase)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)